Targeting calcitonin gene-related peptide: a new era in migraine therapy
Top Cited Papers
- 23 October 2019
- journal article
- review article
- Published by Elsevier BV in The Lancet
- Vol. 394 (10210), 1765-1774
- https://doi.org/10.1016/s0140-6736(19)32504-8
Abstract
No abstract availableKeywords
This publication has 85 references indexed in Scilit:
- Effect of Telcagepant on Spontaneous Ischemia in Cardiovascular Patients in a Randomized StudyHeadache: The Journal of Head and Face Pain, 2011
- Calcitonin gene-related peptide triggers migraine-like attacks in patients with migraine with auraCephalalgia, 2010
- Randomized, controlled trial of telcagepant for the acute treatment of migraineNeurology, 2009
- Potent, Orally Bioavailable Calcitonin Gene-Related Peptide Receptor Antagonists for the Treatment of Migraine: Discovery of N-[(3R,6S)-6-(2,3-Difluorophenyl)-2-oxo-1- (2,2,2-trifluoroethyl)azepan-3-yl]-4- (2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin- 1-yl)piperidine-1-carboxamide (MK-0974)Journal of Medicinal Chemistry, 2007
- The trigeminovascular system and migraine: Studies characterizing cerebrovascular and neuropeptide changes seen in humans and catsAnnals of Neurology, 1993
- Release of vasoactive peptides in the extracerebral circulation of humans and the cat during activation of the trigeminovascular systemAnnals of Neurology, 1988
- Calcitonin gene related peptide inhibits basal, pentagastrin, histamine, and bethanecol stimulated gastric acid secretion.Gut, 1985
- Calcitonin gene-related peptide is a potent vasodilatorNature, 1985
- Stimulation of noradrenergic sympathetic outflow by calcitonin gene-related peptideNature, 1983
- Production of a novel neuropeptide encoded by the calcitonin gene via tissue-specific RNA processingNature, 1983